Eloise Mclennan

Roivant wins FDA approval for first targeted dermatomyositis treatment After a series of bumps in the road, Roviant and Priovant Therapeutics have finally secured US approval for the once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for adults ... See more

ViiV wins US approval for HIV treatment in newborn babies The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg, including eligible newborns from birth. The approval allows dolut... See more

Spyre deprioritises arthritis drug after Phase 2 results Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road after phase 2 data fell short of the company’s target for prioritising the drug a... See more

Jazz secures FDA approval for Ziihera in first-line HER2-positive GEA Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera for people with advanced HER2-positive gastroesophageal adenocarcinoma. The FDA’s decis... See more

FDA greenlights Roche’s biomarker blood test for Alzheimer's Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care, giving clinicians in the US a new way to assess amyloid pathology. The El... See more